Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15370081 | 0.94 | CYP3A4 (0.45) | CYP3A4CYP2C9 | |
| SCHEMBL12069131 | 0.91 | CYP3A4 (0.49) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL2708741 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL13070593 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL10146013 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL206605 | 0.89 | CYP3A4 (0.61) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12069129 | 0.89 | PRCP (0.42) | — | |
| SCHEMBL16572622 | 0.86 | CYP3A4 (0.62) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL12068544 | 0.86 | CYP3A4 (0.62) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 | |
| SCHEMBL15373048 | 0.86 | CYP3A4 (0.62) | CYP3A4CYP2C9NR1I2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| WO-2011150243-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | CYP3A4 2538/4885CYP2C9 3984/4885NR1I2 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.